We’ve recently updated our valuation analysis.

Galecto Valuation

Is GLTO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLTO?

Other financial metrics that can be useful for relative valuation.

GLTO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does GLTO's PB Ratio compare to its peers?

The above table shows the PB ratio for GLTO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.3x
APGN Apexigen
3.8xn/aUS$39.2m
LUMO Lumos Pharma
0.6x-1.7%US$40.3m
AMTI Applied Molecular Transport
0.5x-1.0%US$40.5m
CNTB Connect Biopharma Holdings
0.2x-2.8%US$40.5m
GLTO Galecto
0.5x-25.2%US$39.4m

Price-To-Book vs Peers: GLTO is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (2.3x).


Price to Earnings Ratio vs Industry

How does GLTO's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.5%
n/an/an/a

Price-To-Book vs Industry: GLTO is good value based on its Price-To-Book Ratio (0.5x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is GLTO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLTO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GLTO's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of GLTO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GLTO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GLTO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GLTO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.54
US$8.67
+462.8%
35.7%US$13.00US$6.00n/a3
Nov ’23US$2.01
US$9.00
+348.9%
32.7%US$13.00US$6.00n/a3
Oct ’23US$1.89
US$9.00
+376.2%
32.7%US$13.00US$6.00n/a3
Sep ’23US$2.28
US$9.00
+294.7%
32.7%US$13.00US$6.00n/a3
Aug ’23US$1.69
US$10.00
+491.7%
43.2%US$16.00US$6.00n/a3
Jul ’23US$1.70
US$10.33
+507.8%
40.5%US$16.00US$6.00n/a3
Jun ’23US$1.30
US$11.00
+746.2%
37.1%US$16.00US$6.00n/a3
May ’23US$1.68
US$11.67
+594.4%
35.9%US$16.00US$6.00n/a3
Apr ’23US$2.30
US$11.67
+407.2%
35.9%US$16.00US$6.00n/a3
Mar ’23US$1.84
US$11.67
+534.1%
35.9%US$16.00US$6.00n/a3
Feb ’23US$2.48
US$12.00
+383.9%
31.2%US$16.00US$7.00n/a3
Jan ’23US$3.03
US$12.67
+318.0%
31.8%US$16.00US$7.00n/a3
Dec ’22US$2.64
US$12.67
+379.8%
31.8%US$16.00US$7.00n/a3
Nov ’22US$3.37
US$12.67
+275.9%
31.8%US$16.00US$7.00US$2.013
Oct ’22US$3.52
US$12.67
+259.8%
31.8%US$16.00US$7.00US$1.893
Sep ’22US$4.50
US$12.67
+181.5%
31.8%US$16.00US$7.00US$2.283
Aug ’22US$4.29
US$15.00
+249.7%
14.4%US$17.00US$12.00US$1.693
Jul ’22US$5.00
US$15.00
+200.0%
14.4%US$17.00US$12.00US$1.703
Jun ’22US$5.08
US$16.33
+221.5%
22.5%US$21.00US$12.00US$1.303
May ’22US$5.72
US$16.33
+185.5%
22.5%US$21.00US$12.00US$1.683
Apr ’22US$6.04
US$16.33
+170.4%
22.5%US$21.00US$12.00US$2.303
Mar ’22US$10.98
US$25.67
+133.8%
13.2%US$29.00US$21.00US$1.843
Feb ’22US$12.49
US$25.67
+105.5%
13.2%US$29.00US$21.00US$2.483
Jan ’22US$12.51
US$25.67
+105.2%
13.2%US$29.00US$21.00US$3.033
Dec ’21US$14.68
US$25.67
+74.8%
13.2%US$29.00US$21.00US$2.643

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies